Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Pharmacokinetic evaluation of pemetrexed

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
INTRODUCTION: Pemetrexed is a multi-targeted antifolate cytotoxic agent that has demonstrated activity in a number of very common cancer types including NSCLC in both first- and second-line settings and in the treatment of malignant mesothelioma. AREAS COVERED: This article focuses on all of the currently published pharmacokinetic data of pemetrexed reviewing a number of different scenarios and patient populations. All the articles reviewed in this manuscript are from peer-reviewed English-spoken literature without any limitations to the time of publication. EXPERT OPINION: Pemetrexed's clearance correlates with renal function and it may be safely used with vitamin supplementation in patients with creatinine clearance ≥ 45 ml/min. The pharmacokinetics of pemetrexed is also largely unchanged in third-space fluids and can be feasibly and safely administered in combination with several other cytotoxic or targeted agents. It is the author's opinion that pemetrexed is already a valuable cytotoxic agent which has proved useful in several malignancies. However, future trials might expand on the combined use of pemetrexed with other targeted agents that could be beneficial to other selected patients harboring relevant mutations or other biological features.
OriginalsprogEngelsk
TidsskriftExpert Opinion on Drug Metabolism & Toxicology
Vol/bind7
Udgave nummer7
Sider (fra-til)919-28
Antal sider10
ISSN1742-5255
DOI
StatusUdgivet - jul. 2011

ID: 33271742